Literature DB >> 2691515

Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer.

F Porzsolt1, G Meuret, E D Kreuser, S Mende, L Buchelt, P Strigl, M Redenbacher, F Klumpp, M Schmelz, R Knöchelmann.   

Abstract

In a multicenter study we used a consensus protocol including more than five subsequent therapeutic steps for treatment of patients with advanced breast cancer. A total of 335 evaluable patients from 27 participating hospitals were allocated to a low- or high-risk group, receiving different therapies during the initial phase of treatment. About half of these patients were treated without protocol violations (compliers). The protocol non-compliers were divided into three groups: those receiving more intensive therapy than recommended, those with similarly intensive, and those with less intensive therapy. The reasons for protocol violations were analysed. The intensity of the therapy given actually was correlated with the survival of subgroups. Median survival times were significantly longer in 208 low-risk than in 127 high-risk patients (P less than 0.0001), marginally longer in 165 compliers than in 170 non-compliers (P less than 0.04), significantly longer in low-risk compliers than in low-risk non-compliers (P = 0.002), and significantly shorter in high-risk compliers than in high-risk non-compliers (P = 0.007). Survival of all subgroups of low-risk non-compliers was the same regardless of the actual therapies given. The survival of high-risk patients who received less intensive therapy was significantly longer than that of high-risk compliers (P = 0.015). After six cycles of successful chemotherapy there was no difference, either in time to progression or in survival, between patients who had received either maintenance therapy or no therapy. We postulate that the groups of low-risk and high-risk patients comprised patients with different prognoses. Among low-risk patients, survival of the subgroup with poor prognosis (low-risk non-compliers) was not influenced by therapy. Among high-risk patients, a subgroup with poor prognosis may have been overtreated by using standard chemotherapies as recommended in our consensus protocol.

Entities:  

Mesh:

Year:  1989        PMID: 2691515     DOI: 10.1007/bf00391359

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  The dose dilemma.

Authors:  G P Canellos
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

2.  A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.

Authors:  D Rosner; T Nemoto; W W Lane
Journal:  Cancer       Date:  1987-03-01       Impact factor: 6.860

Review 3.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

4.  Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.

Authors:  H S Moseley; M E Peetz; E J Keenan; A E Awrich; W S Fletcher
Journal:  Am J Surg       Date:  1980-07       Impact factor: 2.565

Review 5.  Dose-response in the treatment of breast cancer: a critical review.

Authors:  I C Henderson; D F Hayes; R Gelman
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

6.  Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.

Authors:  I C Henderson; R Gelman; G P Canellos; E Frei
Journal:  Cancer Treat Rep       Date:  1981

7.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

8.  Cyclical combination chemotherapy for advanced breast carcinoma.

Authors:  G P Canellos; V T Devita; G L Gold; B A Chabner; P S Schein; R C Young
Journal:  Br Med J       Date:  1974-02-09

9.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

Authors:  K D Swenerton; S S Legha; T Smith; G N Hortobagyi; E A Gehan; H Y Yap; J U Gutterman; G R Blumenschein
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

10.  The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

Authors:  J M Howat; M Harris; R Swindell; D M Barnes
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

View more
  1 in total

1.  The impact of a supplementary medication review and counselling service within the oncology outpatient setting.

Authors:  H Read; S Ladds; B Rhodes; D Brown; J Portlock
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.